Oligo(Lactic Acid)8-Docetaxel Prodrug-Loaded PEG-b-PLA Micelles for Prostate Cancer
Posted by Adam Awdish on
Innovative Grade US Origin Rat Sprague Dawley Plasma and Pooled Human Plasma (Blood Derived) from Innovative Research were used in the following study:
Oligo(Lactic Acid)8-Docetaxel Prodrug-Loaded PEG-b-PLA Micelles for Prostate Cancer
Lauren Repp, Christopher J. Unterberger, Zhengqing Ye, John B. Feltenberger, Steven M. Swanson, Paul C. Marker and Glen S. Kwon
Nanomaterials
October 17, 2021
Despite the progress medical science has made over the years in the field of cancer treatment, chemotherapy remains to be one of the most common methods used to combat cancer. An issue that various anticancer drug classes still face, however, is that many of these treatments are not very water soluble and thus need to be administered in large doses for a therapeutic concentration of the drug to be absorbed by the body. By administering large doses, however, the potential for unwanted side effects to present themselves increases alongside the chance that side effects that do show up become more severe.
To address this problem, there has been an increase in interest toward the potential to utilize nanotechnologies to create water-soluble carriers for small hydrophobic injectable drugs. In this recent study, researchers created a novel prodrug aimed at improving the stability of micelles used in prostate cancer treatment. Their carrier proved helpful in both preventing early deterioration as well as maintaining drug concentration during treatment.
Related products available from Innovative Research also include:
Innovative Grade US Origin Mouse Swiss Webster Plasma